top of page

Tracking recent β-thal and CALD gene therapy launches with bluebird’s CEO

Aug 8, 2023
1 min read

Andrew Obenshain describes key metrics bluebird is seeing early in the launch of two of its gene therapies on its Q2 earnings day.

https://vimeo.com/852812571

Recent Posts

Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months

Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months

Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data

Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page